CROSSWALK DOCUMENT FOR CMS 10110

#	FORM#	CHANGE	RATIONALE
1	Supporting Statement A	Supporting document details were updated to reflect more accurate estimates of burden and the number of respondents. • The number of respondents was increased to 300 from 180.	CMS revised the cost burden and reporting estimates to allow for an increase in the number of respondents due to growth in the number of Part B drugs, more niche drugs from smaller manufacturers, and payments for ESRP, OTP, etc.
2	Addendum A	Added 2 new FDA approval types to the drop down list of the FDA Approval Type column in Addendum A to identify more FDA approval types. Corresponding field instructions on tab 2 of Addendum A "Column Instructions" were also revised to reflect this update. **FDA Approval Type**	CMS revised this field to better classify drug and biological products.
3	Addendum A	Deleted descriptive data field. **Descriptive Data Corrected**	This field is no longer necessary.